Sorrento Therapeutics, Inc. filed its 10-K on Mar 16, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 USD | +7.14% | +9.49% | -87.85% |
15/03 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
12/03 | News Highlights : Top Company News of the Day - Tuesday at 5 AM ET | DJ |
1st Jan change | Capi. | |
---|---|---|
-87.85% | 8.16M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- SRNE Stock
- News Sorrento Therapeutics, Inc.
- Sorrento Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt